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Determining an immunologic correlate of protection against Plasmodium falciparum malaria has been the holy grail
of natural infection studies, and sought after as an endpoint for malaria vaccine trials. An in vitro assay that provides
an accurate and precise assessment of protective immunity to malaria would make smaller, short-duration studies
feasible, rather than the currently powered study designs that use morbidity or mortality as outcomes. Such a
biomarker would be especially desirable in situations where malaria control measures that result in decreases in
clinical endpoints and putatively waning protective immunity have been implemented. In an article published in
BMC Medicine, Osier and colleagues addressed this problem, and demonstrated that antibodies promoting opsonic
phagocytosis of merozoites provide a functional link between antigen-specific responses and protection. Understanding
the mechanisms conferring protection against malaria not only improves our knowledge of basic human immunology,
but promises to help in the design of an effective malaria vaccine.
Please see related article: http://www.biomedcentral.com/content/pdf/1741-7015-12-108.pdf.
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One of the reasons that malaria vaccine development is
so challenging is the enormous complexity of the host–
parasite interaction. The parasite itself has over 5,000
open reading frames, some of which are differentially
expressed during the numerous distinct life-cycle stages
within the human host. Even within the cycling erythro-
cyte stage that can create the febrile disease, the parasite
expresses different antigens as an invading merozoite, as
a growing trophozoite, and as an organizing schizont.
This remarkable life-cycle complexity, coupled with an
almost unequalled degree of antigenic variability within
the global population of parasites, allows the parasite to
evade many actions of the host’s immune system.
Thus, unlike many other infectious diseases, survival
of one or more bouts of febrile malaria disease does
not provide sterile protection against further disease or* Correspondence: ann.moormann@umassmed.edu; ann.stewart@usuhs.edu
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article, unless otherwise stated.further infection. Although still only partially under-
stood, repeated exposure does change the immune bal-
ance between the parasite and its host. Because children
in endemic areas age in the context of repeated infec-
tion, they gradually acquire the abilities both to control
parasitemia and to resist being clinically ill [1-3]. This
gradual acquisition of protection from disease, although
not necessarily from infection – and thus referred to as
partial immunity – is thought to involve both cellular-
and antibody-mediated mechanisms. However, a domin-
ant role for anti-malarial antibodies was demonstrated
most clearly over five decades ago by the immediate and
dramatic clinical and parasitological improvement of
Thai children transfused with immunoglobulin from en-
demic adults [4].Field testing functional antibody assays for malaria
Antibody generation has therefore remained an import-
ant goal for blood-stage malaria vaccination efforts.
Simple anti-repeat region antibodies correlate fairly well
with the protection afforded by the most advanced mal-
aria vaccine candidate to date, GlaxoSmithKline’s RTS,S,
but the paradoxically consistent presence of individualsed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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antibody responses makes this a less than ideal predictive
biomarker [5] for this sporozoite-stage vaccine. For blood-
stage antigens, although high antibody titers can protect
against challenge with the cognate antigens [6], overall ti-
ters against the dominant merozoite surface and invasion
antigens have correlated poorly with protection from re-
infection or disease when measured by simple ELISA [7],
making this assay an unreliable surrogate for protection.
To date, the only in vitro methods to evaluate the func-
tionality of antibodies to the blood-stage parasite are the
growth inhibition assay (GIA), which measures the ability
of antibodies to slow the expansion of P. falciparum para-
sites cultured in human erythrocytes in the incubator [8],
and the antibody-dependent cellular cytotoxicity (ADCC)
assay, which has been difficult to generalize to the field
[9]. In their current paper, Osier and colleagues [10] have
described a new assay, the opsonic phagocytosis assay
(OPA), taking advantage of the logical necessity that
in vivo, responses include not just the antibodies them-
selves but the other immune cells with which they inter-
act, thus making this assay more biologically relevant.
This new functional assay measures the ability of anti-
bodies to opsonize freshly isolated live merozoites for
phagocytosis by macrophages in short-term culture. The
authors have carefully characterized this assay, and found
that it works with both freshly isolated macrophages
within lymphocyte mixtures and with an isolated macro-
phage cell line. It appears readily reproducible to any la-
boratory with cell and malaria culture capabilities and a
flow cytometer.
The most compelling evidence presented by Osier and
colleagues are the correlations within the context of two
independent longitudinal cohort studies conducted on
the coast in Kenya. The naturally acquired responses
measured by this OPA correlated with the ability to re-
sist clinical illness in both groups of children residing in
this malaria endemic area. Activity in OPA significantly
correlated with IgG ELISA but had a weak correlation
with GIA (Spearman’s rho −0.358, P = 0.041). The addition
of this novel functional assay as a biomarker seems a lo-
gical step towards a better understanding of the various
specificities involved in the development of protective im-
munity to malaria.
Although the correlation between naturally acquired
partial protection and the results of OPA is very sug-
gestive, the link predicting protection against malaria
induced by a vaccine presenting a limited number of anti-
gens remains untested. It is possible that a vaccine candi-
date might induce antibodies that perform well in the
OPA, yet fail to predict the outcome of a challenge infec-
tion, as has been the case with GIA and anti-malarial
antibodies in general. Caution in generalizing to the
in vivo situation for vaccine development is warrantedbecause of the relatively short transit time (less than
10 minutes) of merozoites between schizont rupture and
re-invasion, although the short duration of the assay may
functionally mimic this. Because it is an assay that utilizes
a whole, living merozoite, its applicability to screen for
efficacy of a single-allele, single-antigen vaccine is diffi-
cult to determine. Thus, this tool should be championed
as a functional assay that, perhaps through future antigen
add-back or blocking experiments, may help dissect the
diverse antibody responses developing in sequentially ex-
posed individuals to determine which of them are func-
tionally important in resisting disease. This work also sets
the stage to develop similar opsonization assays against the
infected red blood cell, which is presented to the host im-
mune responses for a considerably longer duration.
Conclusions
In the headlong race to develop potential malaria vac-
cine candidates, the as yet undiscovered ‘golden chalice’
remains an in vitro assay that can, if not predict the effi-
cacy of a vaccine, at least correlate well with it. One of
the perennial frustrations of those seeking to understand
the interaction of the malaria parasite with the human
immune system is its enormous complexity and the limi-
tations in the tools currently available with which to dis-
sect that complexity. Whether for vaccine development
or for understanding the basic immunology that under-
lies the gradual acquisition of partial resistance to the
disease manifestations of malaria parasitemia, the tech-
nical advance described in the current paper by Osier et al.
[10] represents a new tool in the armamentarium of func-
tional immunological assays for malaria.
Abbreviations
ADCC: Antibody-dependent cellular cytotoxicity; ELISA: Enzyme-linked
immunosorbent assay; GIA: Growth inhibition assay; IgG: Immunoglobulin G;
OPA: Opsonic phagocytosis assay.
Competing interests
The authors declare that they have no competing interests. The views
expressed are those of the author(s) and do not necessarily reflect the
official views of the Uniformed Services University of the Health Sciences
or the Department of Defense.
Received: 17 July 2014 Accepted: 17 July 2014
Published: 8 August 2014
References
1. Artavanis-Tsakonas K, Tongren JE, Riley EM: The war between the malaria
parasite and the immune system: immunity, immunoregulation and
immunopathology. Clin Experiment Immunol 2003, 133:145–152.
2. Goncalves BP, Huang CY, Morrison R, Holte S, Kabyemela E, Prevots DR,
Fried M, Duffy PE: Parasite burden and severity of malaria in Tanzanian
children. New Engl J Med 2014, 370:1799–1808.
3. Marsh K, Kinyanjui S: Immune effector mechanisms in malaria.
Parasite Immunol 2006, 28:51–60.
4. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H,
Chantavanich P, Foucault C, Chongsuphajaisiddhi T, Druilhe P: Parasitologic
and clinical human response to immunoglobulin administration in
falciparum malaria. Am J Trop Med Hyg 1991, 45:297–308.
Moormann and Stewart BMC Medicine 2014, 12:134 Page 3 of 3
http://www.biomedcentral.com/1741-7015/12/1345. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T,
Krzych U, Delchambre M, Voss G, Dowler MG, Palensky J, Wittes J, Cohen J,
Ballou WR, RTS,S Malaria Vaccine Evaluation Group: Efficacy of recombinant
circumsporozoite protein vaccine regimens against experimental
Plasmodium falciparum malaria. J Infect Dis 2001, 183:640–647.
6. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK,
Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A,
Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y,
Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J,
Thompson D, Dube T, Soisson L, et al: A field trial to assess a blood-stage
malaria vaccine. New Engl J Med 2011, 365:1004–1013.
7. Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM: Antibodies to
blood stage antigens of Plasmodium falciparum in rural Gambians and
their relation to protection against infection. Trans R Soc Trop Med Hyg
1989, 83:293–303.
8. Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK,
Mullen GE, Orcutt A, Muratova O, Awkal M, Zhou H, Wang J, Stowers A,
Long CA, Mahanty S, Miller LH, Saul A, Durbin AP: Phase 1 clinical trial of
apical membrane antigen 1: an asexual blood-stage vaccine for
Plasmodium falciparum malaria. Infect Immun 2005, 73:3677–3685.
9. Druilhe P, Bouharoun-Tayoun H: Antibody-dependent cellular inhibition
assay. Methods Mol Med 2002, 72:529–534.
10. Osier FH, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, McCallum FJ,
Reiling L, Jaworowski A, Anders RF, Marsh K, Beeson JG: Opsonic
phagocytosis of Plasmodium falciparum merozoites: mechanism in
human immunity and a correlate of protection against malaria. BMC
Med 2014, 12:108.
doi:10.1186/s12916-014-0134-1
Cite this article as: Moormann and Stewart: The hunt for protective
correlates of immunity to Plasmodium falciparum malaria. BMC Medicine
2014 12:134.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
